Skip to main navigation
Skip to search
Skip to main content
Fox Chase Cancer Center Home
Help & FAQ
Home
Profiles
Research Units
Research Resources
Research Outputs
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
Everolimus in the treatment of metastatic thymic epithelial tumors
Jessica A. Hellyer
, Madhu M. Ouseph
,
Sukhmani K. Padda
, Heather A. Wakelee
Hematology Oncology
Cancer Signaling and Microenvironment (CSM)
Stanford University
Research output
:
Contribution to journal
›
Article
›
peer-review
17
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Everolimus in the treatment of metastatic thymic epithelial tumors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Therapeutic Procedure
100%
Everolimus
100%
Epithelioma
100%
Patient
87%
Neoplasm
37%
Thymic Carcinoma
37%
Gene
25%
Overall Survival
25%
Inpatient
25%
Time to Treatment
25%
Next Generation Sequencing
25%
Analysis
12%
Combination Therapy
12%
Association
12%
Mammalian Target of Rapamycin
12%
Mammalian Target of Rapamycin Inhibitor
12%
Adverse Event
12%
Experience
12%
Toxicity
12%
Autoimmune Disease
12%
Biological Marker
12%
Patient Selection
12%
Thymoma
12%
Pneumonia
12%
Autoimmunity
12%
Thymoma
12%
Pharmacology, Toxicology and Pharmaceutical Science
Everolimus
100%
Epithelium Tumor
100%
Neoplasm
50%
Carcinoma
37%
Overall Survival
25%
Mammalian Target of Rapamycin Inhibitor
12%
Adverse Event
12%
Toxicity
12%
Autoimmune Disease
12%
Biological Marker
12%
Thymoma
12%
Pneumonia
12%